Press Releases

Date Title View
Toggle Summary Second Sight Receives Approval from Bundesinstitut für Arzneimittel und Medizinprodukte in Germany to Begin Study to Implant and Evaluate Argus II in Better-Sighted Retinitis Pigmentosa Patients
SYLMAR, Calif. --(BUSINESS WIRE)--Oct. 17, 2017-- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received
View HTML
Toggle Summary Second Sight to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York on September 12th
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that Dr.
View HTML
Toggle Summary Second Sight Receives Conditional FDA Approval to Begin First Orion Human Clinical Study
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced that the Company has received conditional
View HTML
Toggle Summary Second Sight Reports Second Quarter 2017 Financial Results
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today reported financial results for the three- and six-month
View HTML
Toggle Summary Second Sight Announces Market Entry into Russia with First Implant of Argus II Retinal Prosthesis System
- Marks Continued Global Expansion of Argus II for Individuals Blinded by Retinitis Pigmentosa - SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to
View HTML
Toggle Summary Second Sight to Discuss Second Quarter 2017 Financial Results on August 1, 2017 Conference Call
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to provide some useful vision to blind patients, will release its second quarter 2017 financial results on Tuesday, August
View HTML
Toggle Summary Second Sight Announces Market Entry into South Korea with Two Implants and Performs Second Implant in Taiwan of Argus II Retinal Prosthesis System
-Marks Continued Expansion of Argus II in Asia - SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today
View HTML
Toggle Summary Second Sight Announces Expansion of Medicare Coverage for Argus II Retinal Prosthesis System to 11 Additional States and the District of Columbia
-- Argus II Can Now Be Covered in Seven of 12 Medicare Administrative Contractor Jurisdictions, representing a total of 28 states, two territories, and the District of Columbia -- SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"),
View HTML
Toggle Summary Second Sight to Present at 18th Annual B. Riley & Co. Institutional Investor Conference
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to provide some useful vision to blind patients, today announced that Will McGuire , President and Chief
View HTML
Toggle Summary Second Sight Reports First Quarter 2017 Financial Results
SYLMAR, Calif. --(BUSINESS WIRE)-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today reported financial results for the three-months
View HTML